15:58:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-19 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-10-10 Extra Bolagsstämma 2024
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-30 Split BGBIO 100:1
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning BGBIO 0.00 NOK
2024-05-23 Årsstämma
2024-02-14 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-22 Kvartalsrapport 2023-Q1
2023-05-22 Årsstämma
2023-04-21 X-dag ordinarie utdelning BGBIO 0.00 NOK
2023-02-16 Bokslutskommuniké 2022
2022-11-15 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-29 X-dag ordinarie utdelning BGBIO 0.00 NOK
2022-04-28 Årsstämma
2022-02-16 Bokslutskommuniké 2021
2022-01-06 Extra Bolagsstämma 2022
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-22 X-dag ordinarie utdelning BGBIO 0.00 NOK
2021-03-19 Årsstämma
2021-02-10 Bokslutskommuniké 2020
2020-12-09 Extra Bolagsstämma 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-19 Kvartalsrapport 2020-Q1
2020-03-17 X-dag ordinarie utdelning BGBIO 0.00 NOK
2020-03-16 Årsstämma
2020-02-11 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-19 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-14 X-dag ordinarie utdelning BGBIO 0.00 NOK
2019-03-13 Årsstämma
2019-02-19 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-15 X-dag ordinarie utdelning BGBIO 0.00 NOK
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-14 Årsstämma
2018-03-09 Extra Bolagsstämma 2018
2018-02-13 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-03-23 X-dag ordinarie utdelning BGBIO 0.00 NOK
2017-03-22 Årsstämma
2016-06-22 X-dag ordinarie utdelning BGBIO 0.00 NOK
2016-06-21 Årsstämma
2015-06-23 X-dag ordinarie utdelning BGBIO 0.00 NOK
2015-06-22 Årsstämma

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
BerGenBio är ett norskt onkologibolag. Idag bedriver bolaget forskning och utveckling av hämmande läkemedel för behandling av aggressiva cancertyper. Bolaget har utvecklat ett flertal produkter vars sammansättning ämnar blockera proteinet AXL, ett protein positivt relaterat med spridning av cancercellerna. Bolaget grundades under 2007 och har sitt huvudkontor i Bergen, Norge.
2023-08-16 07:00:00

Bergen, Norway, 16 August 2023- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2023 on Wednesday 23 August 2023. The briefing will take place at the Conference "Vestland på Børs" at 10:45 am CEST where BerGenBio's senior management team will provide a business update.

The presentation will webcast live, a link will be available at www.bergenbio.com in the Investors/Financial Reports section (https://www.bergenbio.com/investors/financial-reports) and a recording will be available shortly after the webcast has finished.

The second quarter and half year financial report and presentation will be made available on the Company's website in the Investors/Financial Reports section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CEST the same day.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com 

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.